(Q33498278)

27 July 2017

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials (English)

1 reference

chronic obstructive pulmonary disease

27 July 2017

0 references

Leonardo M Fabbri

5

0 references

0 references

6

Fernando J Martinez

1 reference

ORCID Public Data File 2021

27 July 2017

1 reference

author name string

Peter M A Calverley

1

1 reference

27 July 2017

Klaus F Rabe

2

1 reference

27 July 2017

Udo-Michael Goehring

3

1 reference

27 July 2017

Søren Kristiansen

4

1 reference

27 July 2017

M2-124 and M2-125 study groups

7

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

27 July 2017

10

1 reference

inferred from page(s)

published in

The Lancet

1 reference

27 July 2017

374

1 reference

27 July 2017

685-694

1 reference

27 July 2017

9691

1 reference

Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

PDE4 inhibitors: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Subgroup analysis and other (mis)uses of baseline data in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

C-reactive protein and coronary heart disease: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Statistical analysis of COPD exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

Exacerbations and intent-to-treat analyses in randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961255-1

7 January 2021

10.1016/S0140-6736(09)61255-1

Identifiers

DOI

1 reference

27 July 2017

1 reference